Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CAI:PHAR's Gross Margin % is ranked worse than 57.48% of 943
companies
in the Drug Manufacturers industry
Industry Median: 48.54
vs CAI:PHAR: 44.18
Egyptian International Pharmaceutical Investments had a gross margin of 42.39% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Egyptian International Pharmaceutical Investments (CAI:PHAR) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Egyptian International Pharmaceutical Investments had a gross margin of 42.39% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Egyptian International Pharmaceutical Investments Gross Margin % Related Terms
Egyptian International Pharmaceutical Investments Gross Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Egyptian International Pharmaceutical Investments Gross Margin % Chart
Egyptian International Pharmaceutical Investments Annual Data
CAI:PHAR vs ZTS, UTHR, VTRS: Gross Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Egyptian International Pharmaceutical Investments's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Egyptian International Pharmaceutical Investments Gross Margin % vs Drug Manufacturers Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Egyptian International Pharmaceutical Investments (CAI:PHAR) has a Gross Margin % of 42.39% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Egyptian International Pharmaceutical Investments and its competitors. This is near median its historical median of 39.89. Over the past decade, Egyptian International Pharmaceutical Investments' Gross Margin % has ranged from 28.45 to 44.87. According to the industry distribution chart, Egyptian International Pharmaceutical Investments ranks #542 out of 943 companies in the Drug Manufacturers industry, placing it in the top 57.5%.
Is Egyptian International Pharmaceutical Investments' Gross Margin % too high?
Egyptian International Pharmaceutical Investments' current Gross Margin % of 42.39% is near median its 10-year median of 39.89. Over the past 10 years, this metric has ranged from a low of 28.45 to a high of 44.87. The Drug Manufacturers industry median Gross Margin % is 48.54. Egyptian International Pharmaceutical Investments' value of 42.39% is 12.7% below this industry median. Based on the distribution chart, Egyptian International Pharmaceutical Investments ranks #542 out of 943 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Egyptian International Pharmaceutical Investments has a GF Score™ of 70/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Egyptian International Pharmaceutical Investments' Gross Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Egyptian International Pharmaceutical Investments ranks #542 out of 943 companies for Gross Margin %. This places Egyptian International Pharmaceutical Investments in the lower half of its industry. The industry median Gross Margin % is 48.54. Egyptian International Pharmaceutical Investments' value of 42.39% is 12.7% below this benchmark. Historically, Egyptian International Pharmaceutical Investments' own Gross Margin % has ranged from 28.45 to 44.87 over the past decade. While the company's 10-year median is 39.89 vs. the industry median of 48.54, Egyptian International Pharmaceutical Investments has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Drug Manufacturers company?
The median Gross Margin % among Drug Manufacturers companies is 48.54, based on 943 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Egyptian International Pharmaceutical Investments's current Gross Margin % of 42.39% is 12.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Egyptian International Pharmaceutical Investments and its competitors. For the Drug Manufacturers industry, the median Gross Margin % is 48.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Egyptian International Pharmaceutical Investments's current Gross Margin % is 42.39%, which is near median its own 10-year median of 39.89. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Egyptian International Pharmaceutical Investments stock overvalued right now?
Based on GuruFocus' analysis, Egyptian International Pharmaceutical Investments (CAI:PHAR) is currently considered Significantly Overvalued. The stock's GF Value™ is E£59.81, compared to a current price of E£86.07 — trading 43.9% above its estimated fair value. The current Gross Margin % is 42.39%, which is near median its 10-year median of 39.89 and 12.7% below the Drug Manufacturers industry median of 48.54. Egyptian International Pharmaceutical Investments' overall GF Score™ is 70/100 with 12 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Egyptian International Pharmaceutical Investments (CAI:PHAR), the current Gross Margin % is 42.39% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Egyptian International Pharmaceutical Investments (CAI:PHAR) Overvalued in 2026?
Based on GuruFocus' analysis, Egyptian International Pharmaceutical Investments stock appears to be overvalued.
The current stock price of E£86.07 is trading 43.9% above its estimated GF Value™ of E£59.81.
GuruFocus considers Egyptian International Pharmaceutical Investments to be Significantly Overvalued.
Key valuation signals for CAI:PHAR:
Gross Margin %: 42.39% (near median its 10-year median of 39.89)
GF Value™: E£59.81 vs. price of E£86.07 (43.9% above fair value)
Industry Position: 12.7% below the Drug Manufacturers median (#542 of 943)
No single metric tells the full story. See the CAI:PHAR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Egyptian International Pharmaceutical Investments Business Description
Egyptian International Pharmaceutical Investments is an Egypt based company pharmaceutical generic drugs. It holds license agreements with a group of pharmaceutical companies to produce their products locally and replace the imported ones. The company produces dosage forms, Spansule capsules, Antibiotics, Lyophilized Products. It exports its products to African, Asian and East European and Latin American Countries.
70GF Score
Get the complete analysis for CAI:PHAR
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CAI:PHAR has been successfully added to your 
